| Compound | BPC-157 + GHK-Cu + TB-500 |
|---|---|
| Category | Vendor blend (healing peptides) |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
BPC-157 + GHK-Cu + TB-500 is catalogued here as a vendor blend (healing peptides) and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A three-component vendor blend adding the copper peptide GHK-Cu to BPC-157 and TB-500. No published study has tested this trio together in any species.
Mechanism of Action
The stacking rationale combines proposed tissue-repair, tripeptide-copper, and thymosin-fragment mechanisms. Mechanistic overlap and interaction potential are unexamined.
Research and Evidence
There is no trial evidence for the combination — not even animal data. Each component’s individual evidence base is described on its own page.
Safety and Side Effects
Multi-ingredient blends maximize uncertainty: unverified identity, unverified ratios, and no safety database whatsoever.
Frequently Asked Questions
What is the evidence tier of BPC-157 + GHK-Cu + TB-500?
BPC-157 + GHK-Cu + TB-500 is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is BPC-157 + GHK-Cu + TB-500 an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for BPC-157 + GHK-Cu + TB-500?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.